Literature DB >> 15363969

Current strategies in cancer gene therapy.

Anas El-Aneed1.   

Abstract

Cancer gene therapy is the most studied application of gene therapy. Many genetic alterations are involved in the transformation of a normal cell into a neoplastic one. The two main gene groups involved in cancer development are oncogenes and tumor suppressor genes. While the latter eliminates cancerous cells via apoptosis, the former enhances cell proliferation. Therefore, apoptotic genes and anti-oncogenes are widely used in cancer gene therapy. In addition to oncogenes and tumor suppressor genes, chemotherapy and gene therapy can be combined through suicide gene strategy. A suicide gene encodes for a non-mammalian enzyme; this enzyme is used to convert a non-toxic prodrug into its active cytotoxic metabolite within the cancerous cells. Tumor suppressor genes, anti-oncogenes and suicide genes target cancer cells on the molecular level. On the other hand, cancer is immunogenic in nature; therefore, it can also be targeted on the immunological level. Boosting the immune response against cancerous cells is usually achieved via genes encoding for cytokines. Interleukin-12 gene, for example, is one of the most studied cytokine genes for cancer gene therapy applications. DNA vaccines are also used after conventional treatments to eliminate remnant malignant cells. All these therapeutic strategies and other strategies namely anti-angiogenesis and drug resistant genes are briefly reviewed and highlighted in this article.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363969     DOI: 10.1016/j.ejphar.2004.06.054

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

Review 1.  Nanoparticles targeting HLA-G for gene therapy in cancer.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2011-04-17       Impact factor: 3.064

2.  Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents.

Authors:  Göknur Kara; Sema Tuncer; Mustafa Türk; Emir Baki Denkbaş
Journal:  Med Oncol       Date:  2015-03-06       Impact factor: 3.064

Review 3.  Encapsulation of nucleic acids and opportunities for cancer treatment.

Authors:  Lisa Brannon-Peppas; Bilal Ghosn; Krishnendu Roy; Kenneth Cornetta
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

4.  Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.

Authors:  Devanand Sarkar; Zao-Zhong Su; Nicolaq Vozhilla; Eun Sook Park; Pankaj Gupta; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

5.  Effects of orientin and vitexin from Trollius chinensis on the growth and apoptosis of esophageal cancer EC-109 cells.

Authors:  Fang An; Shuhua Wang; Qingqing Tian; Dengxiang Zhu
Journal:  Oncol Lett       Date:  2015-08-18       Impact factor: 2.967

Review 6.  Cancer gene therapy targeting angiogenesis: an updated review.

Authors:  Ching-Chiu Liu; Zan Shen; Hsiang-Fu Kung; Marie C M Lin
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

7.  Bioengineered viral vectors for targeting and killing prostate cancer cells.

Authors:  Kai-xin Zhang; William Jia; Paul S Rennie
Journal:  Bioeng Bugs       Date:  2010-01-04

8.  Apoptotic induction with bifunctional E.coli cytosine deaminase-uracil phosphoribosyltransferase mediated suicide gene therapy is synergized by curcumin treatment in vitro.

Authors:  P Gopinath; Siddhartha Sankar Ghosh
Journal:  Mol Biotechnol       Date:  2007-12-19       Impact factor: 2.695

9.  Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes.

Authors:  Lavanya Y Peddada; Olga B Garbuzenko; David I Devore; Tamara Minko; Charles M Roth
Journal:  J Control Release       Date:  2014-09-01       Impact factor: 9.776

10.  Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.

Authors:  Xiao Li; Yan Liu; Zhongmei Wen; Chang Li; Huijun Lu; Mingyao Tian; Kuoshi Jin; Lili Sun; Pegn Gao; Encheng Yang; Xiaohong Xu; Shifu Kan; Zhuoyue Wang; Yuhang Wang; Ningyi Jin
Journal:  Mol Cancer       Date:  2010-01-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.